GLP-1 medications: use and interest in a representative survey of Finns

Препараты GLP-1: применение и интерес к ним по данным репрезентативного опроса жителей Финляндии
Kirsi Hannele Pietiläinen, Virginia W. Chang, Piia T. Jallinoja
2026-07-07

GLP-1 medicationsobesity treatmentsemaglutidetirzepatideweight-based discrimination
BACKGROUND AND OBJECTIVES: GLP-1-based medications have rapidly reshaped the landscape of obesity treatment. Semaglutide was approved for obesity treatment in 2021 in the US and 2022 in Europe, sparking global interest, and the GLP-1/GIP dual-agonist tirzepatide has demonstrated even greater efficacy. However, survey-based data on who uses or considers these medications-particularly across socioeconomic groups, BMI categories, and weight management experiences-remain limited. SUBJECTS/METHODS: A nationally representative online survey of Finnish adults (n = 1729, of which 1693 were included) was conducted in June 2025 via a market research company using quota sampling. Use and awareness of GLP-1 medications for obesity were measured with a single item listing widely known brands-Ozempic, Wegovy, Zepbound, and Mounjaro-to aid recognition. In regression analyses, current, past, and potential users (n = 322) were combined. RESULTS: In total, 3.5% reported current and 2.0% past use, and 13.5% expressed interest in future use. Notably, ~40% of individuals with obesity reported no interest. Bivariate analysis showed that current use was more common among women, those aged 50-69, those with household income exceeding €70,000, individuals with higher BMI, frequent weight loss attempts, experiences of weight-based discrimination, and self-blame. Multivariable analysis showed that current, past, and potential use had strongest associations with BMI ≥30.0 kg/m², repeated or persistent weight loss attempts, experiences of discriminatory treatment due to weight, self-blaming thoughts and hopeful perceptions of GLP-1 medications. Concern about serious health risks was associated with lower likelihood of use or interest. CONCLUSIONS: GLP-1-based medications are gaining recognition, but uptake remains heterogeneous and many individuals with obesity remain uninterested. Concerns about potential health risks persist. Attitudes toward these medications are shaped not only by weight status but also by prior weight management experiences and perceptions. Clinical communication should be sensitive to these factors.
1
A nationally representative Finnish survey found that 3.5% currently used and 2.0% previously used GLP-1 medications for obesity, while 13.5% were interested in future use.
2
Approximately 40% of respondents with obesity reported no interest in using GLP-1 medications.
3
Concern about serious health risks was associated with lower likelihood of GLP-1 medication use or interest, indicating persistent safety concerns and heterogeneous uptake.
4
Current use was more common among women, adults aged 50–69, higher-income individuals, people with higher BMI, frequent weight-loss attempts, discrimination experiences, and self-blame.
5
Use or interest was most strongly associated with BMI ≥30.0 kg/m², repeated or persistent weight-loss attempts, weight-based discrimination, self-blaming thoughts, and hopeful medication perceptions.

GLP-1-based medications for obesity among Finnish adults

Patterns of use and interest, and their associations with socioeconomic characteristics, BMI, weight-management experiences, perceptions, and health-risk concerns

Publication Details
Publication Date
2026-07-07
Journal
Publisher
ISSN
Cited by
0
Access Type
Author Information
Authors
Kirsi Hannele Pietiläinen
Virginia W. Chang
Piia T. Jallinoja
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%